18F-labelled compound for prostate cancer diagnosis, and use thereof
US10870629B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 18, 2018 |
| Grant date | Dec 22, 2020 |
| Priority date | — |
| Expiry date | Jun 18, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when used in positron emission tomography (PET).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.